ATAI Life Sciences NV
NASDAQ:ATAI
ATAI Life Sciences NV
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company is headquartered in Berlin, Berlin and currently employs 81 full-time employees. The company went IPO on 2021-06-18. The firm is aiming to transform the treatment of mental health disorders.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company is headquartered in Berlin, Berlin and currently employs 81 full-time employees. The company went IPO on 2021-06-18. The firm is aiming to transform the treatment of mental health disorders.
Cash Position: Atai ended Q3 with $304 million in cash and access to a $175 million debt facility, giving the company a runway into 2025.
Pipeline Progress: The company reported initial positive Phase 1 results for GRX-917 and KUR-101 and completed enrollment for a key Phase 2a trial of PCN-101 (R-ketamine) for treatment-resistant depression.
Upcoming Catalyst: Top-line results from the Phase 2a PCN-101 trial are expected around the end of this year, which management views as a potentially significant value inflection point.
Focus on At-Home Use: PCN-101 aims for unsupervised at-home administration, rapid onset, and intermittent dosing, targeting a safety profile comparable to placebo on key side effects.
RL007 Program: Phase 2a for RL007 in CIAS will use FDA-supported endpoints, with doses chosen based on earlier positive biomarker data. The larger Phase 2b is expected to start this year.
Strategic Vision: Management highlighted the importance of combining drug development with digital therapeutics to drive durable behavioral change in mental health.
